Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib

J Thorac Oncol. 2021 Jul;16(7):e51-e54. doi: 10.1016/j.jtho.2021.03.006.

¹ Department of Medicine, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.
² Department of Medicine, University of California Irvine School of Medicine, Orange, California.
³ Caris Life Science Inc, Phoenix, Arizona.
⁴ Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address: [email protected].

No abstract available

Publication types